PDS Biotechnology's HPV-directed immunotherapy is sparking optimism in the biotech industry. Click here to find out why I am ...
In H1 2024, promising randomized Phase I data on TG4050 were presented at AACR 2024 (see poster here). These data provide a robust ... shrinkage in 2 of 6 injected lesions.In combination with ...
Danish clinical-stage techbio firm Evaxion Biotech,which is developing AI-Immunology powered vaccines, announced new clinical ...
The recent ESMO 2024 data highlighted significant advancements in immunotherapy. Check out the results from Merck, BMY, ...
We are excited to see efti in combination with KEYTRUDA now driving a 1.9-fold increase in responses ... The ESMO Proferred ...
PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the ...
AZoRobotics on MSN7d
Evaxion Biotech Reports Positive One-Year Results for AI-Designed Cancer VaccineEvaxion Biotech A/S, a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, announces ...
Cytovation to present safety and efficacy data from CICILIA phase I/IIa clinical trial evaluating CY-101 in solid tumors: Bergen, Norway Monday, September 16, 2024, 18:00 Hrs [IST ...
Results from triple combination of efti, radiotherapy and KEYTRUDA® (pembrolizumab) to be presented at the Connective Tissue ...
Pfizer Inc. (NYSE: PFE) continues to showcase potential practice-changing research and next-generation candidates across its ...
Eight abstracts, including two oral presentations, feature new clinical data from Astellas' oncology portfolio and two lead pipeline programs ac ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback